Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Recombinant Influenza Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement
Details : ImplaVax®-enabled vaccination products leverage Enesi’s innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats such as recombinant H7N9 pandemic influenza vaccine.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 19, 2021
Lead Product(s) : Recombinant Influenza Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : RNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Recipient : Imperial College London
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will investigate the potential of combining Enesi's ImplaVax® technology for the creation of thermostable, solid dose vaccines with RNA vaccines based on Imperial's self-amplifying RNA technology and novel Polyplex DNA/RNA stabilisatio...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
December 18, 2020
Lead Product(s) : RNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Recipient : Imperial College London
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : PRRSV vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : The Pirbright Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Study investigating potential of solid-dose vaccine for porcine reproductive and respiratory syndrome virus (PRRSV) conducted in collaboration with The Pirbright Institute.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 29, 2020
Lead Product(s) : PRRSV vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : The Pirbright Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : University of Adelaide
Deal Size : $0.9 million
Deal Type : Collaboration
Details : This project aims to employ Enesi’s ImplaVax® formulation expertise and platform to create a protective Zika virus DNA vaccine in a solid dose implant format for transcutaneous delivery via a needle-free device.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
September 03, 2020
Lead Product(s) : DNA vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : University of Adelaide
Deal Size : $0.9 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
